LIMES Schlosskliniken stock: fair value
LIK.DEThe fair value of LIMES Schlosskliniken under our model is $243.38, the price is 169% above.
The fair value is an estimate from our model, not a price target.
Daily figure as of 13 Nov 2026
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $173.84 and expensive above $405.63 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $84.55 (cash-flow model) and $402.21 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 7.1%. At 8.1% the fair value would be $236.54, at 6.1% it would be $253.62.
Where the number comes from
Half from the cash-flow model, half from earnings times the industry P/E (19.6).
Ten-year cash-flow model from smoothed free cash flow and its past growth until it reaches 2.1%. Discounted at 7.1% (floor: government bond yield 2.1% plus 5 percentage points, since beta 0.8 times the risk premium would give less); no analyst estimates were available.
Calculate with your own assumptionsThe calculation step by step
With these figures the cash flow model arrives at $84.55 per share: free cash flow for the next ten years, each year discounted to today at 7.1%, plus the terminal value for the years after. The table explains the calculation; it is not a recommendation.
Calculation as a table
| Year | Free cash flow | Source | Discount factor | Present value (discounted at 7.1%) |
|---|---|---|---|---|
| 2026 | $1.57M | extrapolated at −9.4% | 0.9334 | $1.47M |
| 2027 | $1.48M | extrapolated at −5.9% | 0.8712 | $1.29M |
| 2028 | $1.43M | extrapolated at −3.5% | 0.8131 | $1.16M |
| 2029 | $1.4M | extrapolated at −1.8% | 0.7589 | $1.07M |
| 2030 | $1.4M | extrapolated at −0.6% | 0.7083 | $988.5K |
| 2031 | $1.4M | extrapolated at 0.2% | 0.6611 | $924.55K |
| 2032 | $1.41M | extrapolated at 0.8% | 0.6171 | $869.73K |
| 2033 | $1.43M | extrapolated at 1.2% | 0.5760 | $821.46K |
| 2034 | $1.45M | extrapolated at 1.5% | 0.5376 | $778.04K |
| 2035 | $1.47M | extrapolated at 1.7% | 0.5017 | $738.36K |
| Step | Value |
|---|---|
| Sum of present values (ten years) | $10.11M |
| Terminal value: cash flow 2035 × (1 + 2.1%) / (7.1% − 2.1%) | $30.06M |
| Present value of terminal value (× 0.5017) | $15.08M |
| Equity value (sum plus present value of terminal value) | $25.19M |
| Shares (diluted) | 298.0K |
| Value per share (equity value divided by shares) | $84.55 |
| Earnings per share, last twelve months | $20.48 |
| × 19.6 (industry P/E) | $402.21 |
| Fair value (average of both parts) | $243.38 |
The model uses free cash flow after interest, which belongs to shareholders, discounted at the cost of equity. Net debt is therefore not deducted again.
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 10 Nov 2026, previously Neutral
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.